473 related articles for article (PubMed ID: 11553788)
1. Introduction of human apolipoprotein E4 "domain interaction" into mouse apolipoprotein E.
Raffai RL; Dong LM; Farese RV; Weisgraber KH
Proc Natl Acad Sci U S A; 2001 Sep; 98(20):11587-91. PubMed ID: 11553788
[TBL] [Abstract][Full Text] [Related]
2. Effect of domain interaction on apolipoprotein E levels in mouse brain.
Ramaswamy G; Xu Q; Huang Y; Weisgraber KH
J Neurosci; 2005 Nov; 25(46):10658-63. PubMed ID: 16291938
[TBL] [Abstract][Full Text] [Related]
3. Human apolipoprotein E4 domain interaction. Arginine 61 and glutamic acid 255 interact to direct the preference for very low density lipoproteins.
Dong LM; Weisgraber KH
J Biol Chem; 1996 Aug; 271(32):19053-7. PubMed ID: 8702576
[TBL] [Abstract][Full Text] [Related]
4. Plasma ApoE4 Levels Are Lower than ApoE2 and ApoE3 Levels, and Not Associated with Plasma Aβ40/42 Ratio as a Biomarker of Amyloid-β Amyloidosis in Alzheimer's Disease.
Nakamura T; Kawarabayashi T; Ueda T; Shimomura S; Hoshino M; Itoh K; Ihara K; Nakaji S; Takatama M; Ikeda Y; Shoji M
J Alzheimers Dis; 2023; 93(1):333-348. PubMed ID: 36970894
[TBL] [Abstract][Full Text] [Related]
5. Interaction of nascent ApoE2, ApoE3, and ApoE4 isoforms expressed in mammalian cells with amyloid peptide beta (1-40). Relevance to Alzheimer's disease.
Aleshkov S; Abraham CR; Zannis VI
Biochemistry; 1997 Aug; 36(34):10571-80. PubMed ID: 9265639
[TBL] [Abstract][Full Text] [Related]
6. Human apolipoprotein E. Role of arginine 61 in mediating the lipoprotein preferences of the E3 and E4 isoforms.
Dong LM; Wilson C; Wardell MR; Simmons T; Mahley RW; Weisgraber KH; Agard DA
J Biol Chem; 1994 Sep; 269(35):22358-65. PubMed ID: 8071364
[TBL] [Abstract][Full Text] [Related]
7. Apolipoprotein E in lipoprotein metabolism, health and cardiovascular disease.
Marais AD
Pathology; 2019 Feb; 51(2):165-176. PubMed ID: 30598326
[TBL] [Abstract][Full Text] [Related]
8. Apolipoprotein E4 domain interaction occurs in living neuronal cells as determined by fluorescence resonance energy transfer.
Xu Q; Brecht WJ; Weisgraber KH; Mahley RW; Huang Y
J Biol Chem; 2004 Jun; 279(24):25511-6. PubMed ID: 15054100
[TBL] [Abstract][Full Text] [Related]
9. Osteoprotegerin inactivation accelerates advanced atherosclerotic lesion progression and calcification in older ApoE-/- mice.
Bennett BJ; Scatena M; Kirk EA; Rattazzi M; Varon RM; Averill M; Schwartz SM; Giachelli CM; Rosenfeld ME
Arterioscler Thromb Vasc Biol; 2006 Sep; 26(9):2117-24. PubMed ID: 16840715
[TBL] [Abstract][Full Text] [Related]
10. Human apolipoprotein E isoforms differentially affect bone mass and turnover in vivo.
Dieckmann M; Beil FT; Mueller B; Bartelt A; Marshall RP; Koehne T; Amling M; Ruether W; Cooper JA; Humphries SE; Herz J; Niemeier A
J Bone Miner Res; 2013 Feb; 28(2):236-45. PubMed ID: 22991192
[TBL] [Abstract][Full Text] [Related]
11. Apolipoprotein E distribution among human plasma lipoproteins: role of the cysteine-arginine interchange at residue 112.
Weisgraber KH
J Lipid Res; 1990 Aug; 31(8):1503-11. PubMed ID: 2280190
[TBL] [Abstract][Full Text] [Related]
12. Localization of osteoprotegerin, tumor necrosis factor-related apoptosis-inducing ligand, and receptor activator of nuclear factor-kappaB ligand in Mönckeberg's sclerosis and atherosclerosis.
Schoppet M; Al-Fakhri N; Franke FE; Katz N; Barth PJ; Maisch B; Preissner KT; Hofbauer LC
J Clin Endocrinol Metab; 2004 Aug; 89(8):4104-12. PubMed ID: 15292354
[TBL] [Abstract][Full Text] [Related]
13. RANK-Fc: a therapeutic antagonist for RANK-L in myeloma.
Sordillo EM; Pearse RN
Cancer; 2003 Feb; 97(3 Suppl):802-12. PubMed ID: 12548579
[TBL] [Abstract][Full Text] [Related]
14. Stable expression and secretion of apolipoproteins E3 and E4 in mouse neuroblastoma cells produces differential effects on neurite outgrowth.
Bellosta S; Nathan BP; Orth M; Dong LM; Mahley RW; Pitas RE
J Biol Chem; 1995 Nov; 270(45):27063-71. PubMed ID: 7592957
[TBL] [Abstract][Full Text] [Related]
15. Apolipoprotein E: from cardiovascular disease to neurodegenerative disorders.
Mahley RW
J Mol Med (Berl); 2016 Jul; 94(7):739-46. PubMed ID: 27277824
[TBL] [Abstract][Full Text] [Related]
16. Apolipoprotein E isoforms and lipoprotein metabolism.
Phillips MC
IUBMB Life; 2014 Sep; 66(9):616-23. PubMed ID: 25328986
[TBL] [Abstract][Full Text] [Related]
17. Effects of polymorphism on the lipid interaction of human apolipoprotein E.
Saito H; Dhanasekaran P; Baldwin F; Weisgraber KH; Phillips MC; Lund-Katz S
J Biol Chem; 2003 Oct; 278(42):40723-9. PubMed ID: 12917433
[TBL] [Abstract][Full Text] [Related]
18. Apolipoprotein E4 inhibits, and apolipoprotein E3 promotes neurite outgrowth in cultured adult mouse cortical neurons through the low-density lipoprotein receptor-related protein.
Nathan BP; Jiang Y; Wong GK; Shen F; Brewer GJ; Struble RG
Brain Res; 2002 Feb; 928(1-2):96-105. PubMed ID: 11844476
[TBL] [Abstract][Full Text] [Related]
19. Human apolipoprotein E7:lysine mutations in the carboxy-terminal domain are directly responsible for preferential binding to very low density lipoproteins.
Dong J; Balestra ME; Newhouse YM; Weisgraber KH
J Lipid Res; 2000 Nov; 41(11):1783-9. PubMed ID: 11060347
[TBL] [Abstract][Full Text] [Related]
20. Abnormal in vivo metabolism of apolipoprotein E4 in humans.
Gregg RE; Zech LA; Schaefer EJ; Stark D; Wilson D; Brewer HB
J Clin Invest; 1986 Sep; 78(3):815-21. PubMed ID: 3745440
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
